CDNA
Price
$22.93
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
113 days until earnings call
ZOM
Price
$0.12
Change
-$0.00 (-0.00%)
Updated
Nov 5, 04:00 PM (EDT)
2 days until earnings call
Ad is loading...

CDNA vs ZOM

Header iconCDNA vs ZOM Comparison
Open Charts CDNA vs ZOMBanner chart's image
CareDx
Price$22.93
Change-$0.00 (-0.00%)
Volume$938.11K
CapitalizationN/A
Zomedica
Price$0.12
Change-$0.00 (-0.00%)
Volume$141.93K
CapitalizationN/A
View a ticker or compare two or three
CDNA vs ZOM Comparison Chart
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZOM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CDNA vs. ZOM commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Sell and ZOM is a StrongSell.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (CDNA: $22.98 vs. ZOM: $0.12)
Brand notoriety: CDNA and ZOM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 95% vs. ZOM: 80%
Market capitalization -- CDNA: $548.33M vs. ZOM: $137.19M
CDNA [@Medical Specialties] is valued at $548.33M. ZOM’s [@Medical Specialties] market capitalization is $137.19M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 1 FA rating(s) are green whileZOM’s FA Score has 1 green FA rating(s).

  • CDNA’s FA Score: 1 green, 4 red.
  • ZOM’s FA Score: 1 green, 4 red.
According to our system of comparison, CDNA is a better buy in the long-term than ZOM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 4 TA indicator(s) are bullish while ZOM’s TA Score has 2 bullish TA indicator(s).

  • CDNA’s TA Score: 4 bullish, 6 bearish.
  • ZOM’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CDNA is a better buy in the short-term than ZOM.

Price Growth

CDNA (@Medical Specialties) experienced а +0.39% price change this week, while ZOM (@Medical Specialties) price change was -2.52% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.69%. For the same industry, the average monthly price growth was -0.14%, and the average quarterly price growth was -1.28%.

Reported Earning Dates

CDNA is expected to report earnings on Feb 26, 2025.

ZOM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Medical Specialties (+0.69% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($548M) has a higher market cap than ZOM($137M). CDNA YTD gains are higher at: 91.500 vs. ZOM (-40.060). ZOM has higher annual earnings (EBITDA): -11.94M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. ZOM (106M). ZOM has less debt than CDNA: ZOM (1.75M) vs CDNA (34.2M). CDNA has higher revenues than ZOM: CDNA (280M) vs ZOM (24M).
CDNAZOMCDNA / ZOM
Capitalization548M137M400%
EBITDA-84.92M-11.94M712%
Gain YTD91.500-40.060-228%
P/E RatioN/AN/A-
Revenue280M24M1,167%
Total Cash235M106M222%
Total Debt34.2M1.75M1,952%
FUNDAMENTALS RATINGS
CDNA vs ZOM: Fundamental Ratings
CDNA
ZOM
OUTLOOK RATING
1..100
5451
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
3682
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOM's Valuation (28) in the Pharmaceuticals Major industry is significantly better than the same rating for CDNA (100) in the Medical Specialties industry. This means that ZOM’s stock grew significantly faster than CDNA’s over the last 12 months.

ZOM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CDNA (100) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to CDNA’s over the last 12 months.

ZOM's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as CDNA (96) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for ZOM (82) in the Pharmaceuticals Major industry. This means that CDNA’s stock grew somewhat faster than ZOM’s over the last 12 months.

CDNA's P/E Growth Rating (1) in the Medical Specialties industry is significantly better than the same rating for ZOM (100) in the Pharmaceuticals Major industry. This means that CDNA’s stock grew significantly faster than ZOM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAZOM
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZOM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IUSCX12.280.10
+0.82%
Fisher IIG US Sm Cap Eq
TSPTX6.760.01
+0.15%
Transamerica Small Cap Growth I3
FEYAX26.880.01
+0.04%
Fidelity Advisor Asset Manager 85% A
MNVRX30.78-0.01
-0.03%
Madison Investors R6
JCVSX35.67-0.13
-0.36%
JHancock Classic Value R2

ZOM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOM has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOM jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOM
1D Price
Change %
ZOM100%
-0.17%
SNDL - ZOM
38%
Loosely correlated
+2.37%
CDNA - ZOM
30%
Poorly correlated
+1.50%
OSUR - ZOM
30%
Poorly correlated
+0.96%
EBS - ZOM
29%
Poorly correlated
-3.84%
ARAY - ZOM
29%
Poorly correlated
+2.29%
More